Identification of a role for the trans-golgi network in human papillomavirus 16 pseudovirus infection

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 3862-3870

  Day, Patricia M ^a   Thompson, Cynthia D ^a   Schowalter, Rachel M ^a   Lowy, Douglas R ^a   Schiller, John T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DEOXYURIDINE DERIVATIVE; VIRUS ANTIBODY;

ANIMAL CELL; ARTICLE; CELL FUNCTION; CONFOCAL MICROSCOPY; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; TRANS GOLGI NETWORK; VIRION; VIRUS ENTRY; VIRUS GENOME;

BREFELDIN A; CAPSID PROTEINS; CELL LINE; DEOXYURIDINE; FLUORESCENT ANTIBODY TECHNIQUE; FURIN; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICROSCOPY, CONFOCAL; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PROTEIN TRANSPORT; PYRIDINES; QUINOLINES; RAB GTP-BINDING PROTEINS; TRANS-GOLGI NETWORK; VIRUS INTERNALIZATION;

HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; MIRIDAE;

EID: 84875523072     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03222-12     Document Type: Article

References (54)

1. Liu WJ, Gissmann L, Sun XY, Kanjanahaluethai A, Muller M, Doorbar J, Zhou J. 1997. Sequence close to the N-terminus of L2 protein is displayed on the surface of bovine papillomavirus type 1 virions. Virology 227:474-483.
2. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT. 2005. Maturation of papillomavirus capsids. J. Virol. 79:2839-2846.
3. Richards RM, Lowy DR, Schiller JT, Day PM. 2006. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. U. S. A. 103:1522-1527.
4. Kämper N, Day PM, Nowak T, Selinka HC, Florin L, Bolscher J, Hilbig L, Schiller JT, Sapp M. 2006. A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes. J. Virol. 80:759-768.
5. Bienkowska-Haba M, Williams C, Kim SM, Garcea RL, Sapp M. 2012. Cyclophilins facilitate dissociation of the human papillomavirus type 16 capsid protein L1 from the L2/DNA complex following virus entry. J. Virol. 86:9875-9887.
6. Florin L, Becker KA, Lambert C, Nowak T, Sapp C, Strand D, Streeck RE, Sapp M. 2006. Identification of a dynein interacting domain in the papillomavirus minor capsid protein L2. J. Virol. 80:6691-6696.
7. Schneider MA, Florin L, Lambert C. 2011. Identification of the dynein light chains required for human papillomavirus infection. Cell. Microbiol. 13:32-46.
8. Pyeon D, Pearce SM, Lank SM, Ahlquist P, Lambert PF. 2009. Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog. 5:e1000318. doi:10.1371/journal.ppat.1000318.
9. Day PM, Baker CC, Lowy DR, Schiller JT. 2004. Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc. Natl. Acad. Sci. U. S. A. 101:14252-14257.
10. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2005. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol. Med. 119:445-462.
11. Chiron MF, Fryling CM, FitzGerald D. 1997. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J. Biol. Chem. 272: 31707-31711.
12. Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT. 2012. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin. Vaccine Immunol. 19: 1075-1082.
13. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT. 1996. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:5875-5883.
14. Sapp M, Kraus U, Volpers C, Snijders PJ, Walboomers JM, Streeck RE. 1994. Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein. J. Gen. Virol. 75(Part 12):3375-3383.
15. Choudhury A, Dominguez M, Puri V, Sharma DK, Narita K, Wheatley CL, Marks DL, Pagano RE. 2002. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J. Clin. Invest. 109:1541-1550.
16. Progida C, Cogli L, Piro F, De Luca A, Bakke O, Bucci C. 2010. Rab7b controls trafficking from endosomes to the TGN. J. Cell Sci. 123:1480-1491.
17. Spoden G, Freitag K, Husmann M, Boller K, Sapp M, Lambert C, Florin L. 2008. Clathrin-and caveolin-independent entry of human papilloma-virus type 16-involvement of tetraspanin-enriched microdomains (TEMs). PLoS One 3:e3313. doi:10.1371/journal.pone.0003313.
18. Doms RW, Russ G, Yewdell JW. 1989. Brefeldin A redistributes resident and itinerant Golgi proteins to the endoplasmic reticulum. J. Cell Biol. 109:61-72.
19. Lippincott-Schwartz J, Yuan LC, Bonifacino JS, Klausner RD. 1989. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell 56: 801-813.
20. Misumi Y, Miki K, Takatsuki A, Tamura G, Ikehara Y. 1986. Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J. Biol. Chem. 261:11398-11403.
21. Damke H, Klumperman J, von Figura K, Braulke T. 1991. Effects of brefeldin A on the endocytic route. Redistribution of mannose 6-phosphate/ insulin-like growth factor II receptors to the cell surface. J. Biol. Chem. 266:24829-24833.
22. Lippincott-Schwartz J, Yuan L, Tipper C, Amherdt M, Orci L, Klausner RD. 1991. Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic. Cell 67:601-616.
23. Sáenz JB, Sun WJ, Chang JW, Li J, Bursulaya B, Gray NS, Haslam DB. 2009. Golgicide A reveals essential roles for GBF1 in Golgi assembly and function. Nat. Chem. Biol. 5:157-165.
24. Day PM, Lowy DR, Schiller JT. 2003. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 307:1-11.
25. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U. S. A. 89:12180-12184.
26. Campos SK, Chapman JA, Deymier MJ, Bronnimann MP, Ozbun MA. 2012. Opposing effects of bacitracin on human papillomavirus type 16 infection: enhancement of binding and entry and inhibition of endosomal penetration. J. Virol. 86:4169-4181.
27. Bonifacino JS, Rojas R. 2006. Retrograde transport from endosomes to the trans-Golgi network. Nat. Rev. Mol. Cell Biol. 7:568-579.
28. Lombardi D, Soldati T, Riederer MA, Goda Y, Zerial M, Pfeffer SR. 1993. Rab9 functions in transport between late endosomes and the trans Golgi network. EMBO J. 12:677-682.
29. Riederer MA, Soldati T, Shapiro AD, Lin J, Pfeffer SR. 1994. Lysosome biogenesis requires Rab9 function and receptor recycling from endosomes to the trans-Golgi network. J. Cell Biol. 125:573-582.
30. Schelhaas M, Shah B, Holzer M, Blattmann P, Kuhling L, Day PM, Schiller JT, Helenius A. 2012. Entry of human papillomavirus type 16 by actin-dependent, clathrin-and lipid raft-independent endocytosis. PLoS Pathog. 8:e1002657. doi:10.1371/journal.ppat.1002657.
31. Chia PZ, Gasnereau I, Lieu ZZ, Gleeson PA. 2011. Rab9-dependent retrograde transport and endosomal sorting of the endopeptidase furin. J. Cell Sci. 124:2401-2413.
32. Ishii Y, Tanaka K, Kondo K, Takeuchi T, Mori S, Kanda T. 2010. Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody. Virology 406:181-188.
33. Donaldson JG, Lippincott-Schwartz J, Bloom GS, Kreis TE, Klausner RD. 1990. Dissociation of a 110-kD peripheral membrane protein from the Golgi apparatus is an early event in brefeldin A action. J. Cell Biol. 111:2295-2306.
34. Helms JB, Rothman JE. 1992. Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF. Nature 360:352-354.
35. Robinson MS, Kreis TE. 1992. Recruitment of coat proteins onto Golgi membranes in intact and permeabilized cells: effects of brefeldin A and G protein activators. Cell 69:129-138.
36. Laniosz V, Dabydeen SA, Havens MA, Meneses PI. 2009. Human papillomavirus type 16 infection of human keratinocytes requires clathrin and caveolin-1 and is brefeldin A sensitive. J. Virol. 83:8221-8232.
37. Bergant Marušiccaron; M, Ozbun MA, Campos SK, Myers MP, Banks L. 2012. Human papillomavirus L2 facilitates viral escape from late endosomes via sorting nexin 17. Traffic 13:455-467.
38. Bousarghin L, Touze A, Sizaret PY, Coursaget P. 2003. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J. Virol. 77:3846-3850.
39. Selinka HC, Giroglou T, Sapp M. 2002. Analysis of the infectious entry pathway of human papillomavirus type 33 pseudovirions. Virology 299: 279-287.
40. Mizuno-Yamasaki E, Rivera-Molina F, Novick P. 2012. GTPase networks in membrane traffic. Annu. Rev. Biochem. 81:637-659.
41. Chavrier P, Parton RG, Hauri HP, Simons K, Zerial M. 1990. Localization of low molecular weight GTP binding proteins to exocytic and endocytic compartments. Cell 62:317-329.
42. Gorvel JP, Chavrier P, Zerial M, Gruenberg J. 1991. rab5 controls early endosome fusion in vitro. Cell 64:915-925.
43. Bucci C, Thomsen P, Nicoziani P, McCarthy J, van Deurs B. 2000. Rab7: a key to lysosome biogenesis. Mol. Biol. Cell 11:467-480.
44. Ng EL, Gan BQ, Ng F, Tang BL. 2012. Rab GTPases regulating receptor trafficking at the late endosome-lysosome membranes. Cell Biochem. Funct. 30:515-523.
45. Smith JL, Campos SK, Wandinger-Ness A, Ozbun MA. 2008. Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating. J. Virol. 82:9505-9512.
46. Progida C, Nielsen MS, Koster G, Bucci C, Bakke O. 2012. Dynamics of Rab7b-dependent transport of sorting receptors. Traffic 13:1273-1285.
47. Carlton J, Bujny M, Rutherford A, Cullen P. 2005. Sorting nexins-unifying trends and new perspectives. Traffic 6:75-82.
48. Böttcher RT, Stremmel C, Meves A, Meyer H, Widmaier M, Tseng HY, Fassler R. 2012. Sorting nexin 17 prevents lysosomal degradation of beta1 integrins by binding to the beta1-integrin tail. Nat. Cell Biol. 14:584-592.
49. Steinberg F, Heesom KJ, Bass MD, Cullen PJ. 2012. SNX17 protects integrins from degradation by sorting between lysosomal and recycling pathways. J. Cell Biol. 197:219-230.
50. Yin W, Liu LDN, Xu L, Li S, Lin S, Shu X, Pei D. 2012. SNX17 regulates Notch pathway and pancreas development through the retromerdependent recycling of Jag1. Cell Regeneration 1:1-10.
51. Tai AW, Chuang JZ, Sung CH. 1998. Localization of Tctex-1, a cytoplasmic dynein light chain, to the Golgi apparatus and evidence for dynein complex heterogeneity. J. Biol. Chem. 273:19639-19649.
52. Palmer KJ, Hughes H, Stephens DJ. 2009. Specificity of cytoplasmic dynein subunits in discrete membrane-trafficking steps. Mol. Biol. Cell 20:2885-2899.
53. Yeh TY, Chuang JZ, Sung CH. 2005. Dynein light chain rp3 acts as a nuclear matrix-associated transcriptional modulator in a dyneinindependent pathway. J. Cell Sci. 118:3431-3443.
54. Herzig RP, Andersson U, Scarpulla RC. 2000. Dynein light chain interacts with NRF-1 and EWG, structurally and functionally related transcription factors from humans and drosophila. J. Cell Sci. 113(Part 23):4263-4273.